BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Al-Toubah T, Cives M, Strosberg J. Novel immunotherapy strategies for treatment of neuroendocrine neoplasms. Transl Gastroenterol Hepatol 2020;5:54. [PMID: 33073049 DOI: 10.21037/tgh.2019.12.18] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
Number Citing Articles
1 Zhu C, Sandilos G, Williamson J, Emery R, Platoff R, Joneja U, Acharya NK, Lin A, Badach J, Zilberman B, Madzo J, Jelinek J, Zhang P, Hong YK. Novel treatment strategy of targeting epigenetic dysregulation in pancreatic neuroendocrine tumors. Surgery 2023:S0039-6060(22)01037-6. [PMID: 36642656 DOI: 10.1016/j.surg.2022.12.008] [Reference Citation Analysis]
2 Nikolic AL, Gullifer J, Johnson MA, Hii MW. Oesophageal neuroendocrine tumours-case series of a rare malignancy. J Surg Case Rep 2022;2022:rjac582. [PMID: 36570553 DOI: 10.1093/jscr/rjac582] [Reference Citation Analysis]
3 Virarkar M, Gopireddy DR, Morani AC, Alkhasawneh A, Klimkowski SP, Kumar S, Lall C, Bhosale P. Rectal neuroendocrine neoplasms: what the radiologists should know. Abdom Radiol (NY) 2022;47:4016-31. [PMID: 35288791 DOI: 10.1007/s00261-022-03474-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Feola T, Carbonara F, Verrico M, Di Crescenzo RM, Gianno F, Colonnese C, Arcella A, de Alcubierre D, Tomao S, Esposito V, Giangaspero F, Minniti G, Jaffrain-rea M. Immunotherapy for Aggressive and Metastatic Pituitary Neuroendocrine Tumors (PitNETs): State-of-the Art. Cancers 2022;14:4093. [DOI: 10.3390/cancers14174093] [Reference Citation Analysis]
5 Fanciulli G, Modica R, La Salvia A, Campolo F, Florio T, Mikovic N, Plebani A, Di Vito V, Colao A, Faggiano A. Immunotherapy of Neuroendocrine Neoplasms: Any Role for the Chimeric Antigen Receptor T Cells? Cancers 2022;14:3991. [DOI: 10.3390/cancers14163991] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Tarhini AA, Eads JR, Moore KN, Tatard-Leitman V, Wright J, Forde PM, Ferris RL. Neoadjuvant immunotherapy of locoregionally advanced solid tumors. J Immunother Cancer 2022;10:e005036. [PMID: 35973745 DOI: 10.1136/jitc-2022-005036] [Reference Citation Analysis]
7 Tang X, Shao Y, Li D, Ding K. Neoantigen-Based Immunotherapy for a Long-Term Survivor With Pancreatic Neuroendocrine Tumor. Pancreas 2022;51:e99-e101. [PMID: 36395415 DOI: 10.1097/MPA.0000000000002092] [Reference Citation Analysis]
8 Auernhammer CJ, Pavel ME. Immuntherapie bei neuroendokrinen Tumoren. Onkologie 2022;28:660-666. [DOI: 10.1007/s00761-022-01199-4] [Reference Citation Analysis]
9 Di Molfetta S, Feola T, Fanciulli G, Florio T, Colao A, Faggiano A, Nike Group. Immune Checkpoint Blockade in Lung Carcinoids with Aggressive Behaviour: One More Arrow in Our Quiver? J Clin Med 2022;11:1019. [PMID: 35207291 DOI: 10.3390/jcm11041019] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
10 Han R, Liu Q, Lu Y, Peng J, Pan M, Wang G, Chen W, Xiao Y, Yang C, Qian Z. Tumor microenvironment-responsive Ag2S-PAsp(DOX)-cRGD nanoparticles-mediated photochemotherapy enhances the immune response to tumor therapy. Biomaterials 2021;281:121328. [PMID: 34953333 DOI: 10.1016/j.biomaterials.2021.121328] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
11 Marini F, Giusti F, Brandi ML. Epigenetic-based targeted therapies for well-differentiated pancreatic neuroendocrine tumors: recent advances and future perspectives. Expert Rev Endocrinol Metab 2021;:1-13. [PMID: 34554891 DOI: 10.1080/17446651.2021.1982382] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
12 Effraimidis G, Knigge U, Rossing M, Oturai P, Rasmussen ÅK, Feldt-Rasmussen U. Multiple endocrine neoplasia type 1 (MEN-1) and neuroendocrine neoplasms (NENs). Semin Cancer Biol 2021:S1044-579X(21)00112-7. [PMID: 33905872 DOI: 10.1016/j.semcancer.2021.04.011] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
13 Albertelli M, Dotto A, Nista F, Veresani A, Patti L, Gay S, Sciallero S, Boschetti M, Ferone D. "Present and future of immunotherapy in Neuroendocrine Tumors". Rev Endocr Metab Disord 2021;22:615-36. [PMID: 33851319 DOI: 10.1007/s11154-021-09647-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
14 Teran S, Camara Jurado M, Nuñez Sobrino JA. A Patient with an Ileocecal MiNEN and a Synchronous Squamous Non-Small-Cell Lung Cancer: Case Report and Review of the Literature. Case Rep Oncol Med 2021;2021:8896254. [PMID: 33859853 DOI: 10.1155/2021/8896254] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
15 Vitali E, Piccini S, Trivellin G, Smiroldo V, Lavezzi E, Zerbi A, Pepe G, Lania AG. The impact of SST2 trafficking and signaling in the treatment of pancreatic neuroendocrine tumors. Mol Cell Endocrinol 2021;527:111226. [PMID: 33675866 DOI: 10.1016/j.mce.2021.111226] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
16 Han R, Xiao Y, Yang Q, Pan M, Hao Y, He X, Peng J, Qian Z. Ag2S nanoparticle-mediated multiple ablations reinvigorates the immune response for enhanced cancer photo-immunotherapy. Biomaterials 2021;264:120451. [PMID: 33069133 DOI: 10.1016/j.biomaterials.2020.120451] [Cited by in Crossref: 40] [Cited by in F6Publishing: 39] [Article Influence: 13.3] [Reference Citation Analysis]